Official Title
A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients
Brief Summary

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.

Completed
COVID-19
Venous Thromboembolism
Arterial Thrombosis

Drug: Unfractionated Heparin IV

Unfractionated heparin IV targeting an aPTT of 1.5-2.5 times the control

Drug: Enoxaparin 1 mg/kg

Enoxaparin 1 mg/kg SC Q12h

Drug: Clopidogrel

Clopidogrel 300 mg PO x1, then clopidogrel 75 mg PO QD

Drug: Unfractionated heparin SC

Unfractionated heparin 5,000 IU SC TID

Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution

Enoxaparin 40 mg SC QD

Eligibility Criteria

Inclusion Criteria:

1. Age ≥18 years (male or female)

2. Acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)

3. Currently admitted to an intensive care unit (ICU)

Key Exclusion Criteria:

1. Ongoing (>48 hours) or planned full-dose (therapeutic) anticoagulation for any
indication

2. Ongoing or planned treatment with dual antiplatelet therapy

3. Contraindication to antithrombotic therapy or high risk of bleeding due to conditions
including, but not limited to, any of the following:

1. History of intracranial hemorrhage, known CNS tumor or CNS vascular abnormality

2. Active or recent major bleeding within the past 30 days with untreated source

3. Platelet count <70,000 or known functional platelet disorder

4. Fibrinogen <200 mg/dL

5. International normalized ratio (INR) >1.9

4. History of heparin-induced thrombocytopenia

5. Ischemic stroke within the past 2 weeks

Patients who meet the following criterion are excluded from the second randomization
(antiplatelet therapy vs. no antiplatelet therapy):

1. Ongoing or planned antiplatelet therapy, including aspirin monotherapy

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

Brigham and Women's Hospital
Boston, Massachusetts, United States

The TIMI Study Group
NCT Number
MeSH Terms
COVID-19
Thrombosis
Thromboembolism
Venous Thromboembolism
Heparin
Calcium heparin
Enoxaparin
Enoxaparin sodium
Clopidogrel